Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Please Log In/Join Now first, and then use this function!

Find a Clinical Trial

Researching Blood Cancer

Blood cancers form in the bone marrow where blood is made, or in the lymphatic system, which protects us from infections.

Jump to Studies

Leukemia | Lymphoma | Multiple Myeloma

Blood Cancer Clinical Trials

We are currently investigating experimental medications for Multiple Myeloma, Lymphoma and Leukemia.

Multiple Myeloma is a type of blood cancer which forms in plasma cells.
Lymphomas are blood cancers that target the immune system.
Leukemia is a cancer of the blood and bone marrow caused by too many white blood cells, leukemia takes on several forms and can occur in both children and adults.

Thank you for Considering a Clinical Trial

Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).

Here are some options for you to find more information:

Browse the trials available on your own and Click on View Trial Details for more information, including locations that are recruiting patients.
- or -
Let us help you find a trial: Pre-Screen Now and answer a few questions to determine if there is a trial that might be right for you.

Leukemia Trials

017004

Recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-90009-AML-002

Recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

Lymphoma Trials

017004

Recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-220-NHL-001

Recruiting

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-DLBCL-001

Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

NDS-DLBCL-003

Recruiting

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA224-069

Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

View Trial Details

Multiple Myeloma Trials

CA204-008

Recruiting

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

View Trial Details

CC-220-MM-001

Recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92480-MM-001

Recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-93269-MM-001

Recruiting

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

BB2121-MM-002

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

BB2121-MM-003

Recruiting

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92480-MM-002

Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-99712-MM-001

Recruiting

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-98633-MM-001

Recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-95266-MM-001

Recruiting

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

BB2121-MM-007

Recruiting

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92328-MM-001

Recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-MM-002

Not Yet Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

Get updates on clinical trials

Get notified when new studies open that might be right for you

What are you thankful for?

"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...

Silver Linings, Breast Cancer - Survivor

View Story

"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...

Silver Linings, Breast Cancer - Survivor

View Story

"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"

Larry and Nancy, Melanoma

View Story

"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"

Larry and Nancy, Melanoma

View Story

"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"

Lucy, Rheumatoid Arthritis

View Story

"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"

Lucy, Rheumatoid Arthritis

View Story

"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"

Tolley, Melanoma

View Story

"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"

Tolley, Melanoma

View Story

All Stories

Explore Blood Cancer Resources

More About Blood Cancer

By the numbers - More than 1 million new blood cancer cases are expected to be diagnosed globally in 2020, accounting for approximately 6% of all new cancer cases.

Learn More

Leukemia Statistics

Did You Know? Video Series

Bristol Myers Squibb is not affiliated with the creators of this content. The information provided here is for informational purposes only and is not meant to replace a physician's medical advice or imply endorsement. Content in this video may speak to medical topics that are not necessarily related to clinical trials.

Source: NIH (National Institute of Heath) – used with permission 2:53

SELECTED SUPPORT ORGANIZATIONS AND DISEASE INFORMATION

Bristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement. This is not an exhaustive list of resources for this condition. There may be others that you may wish to explore.

National Cancer Institute Multiple Myeloma Overview

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com